Shawn Cross
CIK 1734779 · Chief Financial Officer · last filed 2026-11-03
Shawn Cross is a Chief Financial Officer who has filed 35 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing shows the insider had shares withheld for taxes covering $347.2K of PCRX on Nov 3, 2026. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.5M across reported positions. 15 SEC filings were submitted jointly with Pacira BioSciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PCRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WASHINGTON, DC 20006
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCRX | Chief Financial Officer | 95,801 | $36.46 | $3.49M | -$1.52M | 8 | 2026-11-03 |
| Cyclo Therapeutics, Inc. (CYTHW) Delisted | Director | 136,346 | $0.03 | $4.4K | $0 | 5 | 2025-03-03 |
| Applied Molecular Transport Inc. (AMTI) Delisted | CEO & Chair of the Board | 0 | $0.26 | $0 | -$383.5K | 15 | 2023-12-28 |
Recent Filings
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-11-03 | PCRX | Tax (F) | −9,540 | -$347.2K | EDGAR |
| 2026-04-24 | PCRX | Mixed | — | -$112.7K | EDGAR |
| 2026-04-23 | PCRX | Notice (144) | −12,941 | -$325.6K | EDGAR |
| 2026-04-22 | PCRX | Notice (144) | −1,500 | -$37.5K | EDGAR |
| 2026-04-22 | PCRX | Mixed | — | -$104.2K | EDGAR |
| 2026-04-21 | PCRX | Notice (144) | −2,845 | -$71.1K | EDGAR |
| 2026-04-20 | PCRX | Notice (144) | −7,714 | -$193.9K | EDGAR |
| 2026-02-13 | PCRX | Grant (A) | +49,091 | $0 | EDGAR |
| 2025-12-11 | PCRX | Mixed | — | -$215.5K | EDGAR |
| 2025-12-10 | PCRX | Notice (144) | −9,104 | -$228.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.